PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Petros Pharmaceuticals Inc (PTPI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US71678J1007

Sector

Healthcare

IPO Date

Dec 2, 2020

Highlights

Market Cap

$1.79M

EPS (TTM)

-$3.80

Total Revenue (TTM)

$4.39M

Gross Profit (TTM)

$3.44M

EBITDA (TTM)

-$2.38M

Year Range

$0.12 - $1.76

Target Price

$1.00

Short %

7.02%

Short Ratio

0.55

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Petros Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-61.63%
9.81%
PTPI (Petros Pharmaceuticals Inc)
Benchmark (^GSPC)

Returns By Period

Petros Pharmaceuticals Inc had a return of -66.49% year-to-date (YTD) and -91.70% in the last 12 months.


PTPI

YTD

-66.49%

1M

-58.75%

6M

-61.74%

1Y

-91.70%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.01%

1M

1.13%

6M

9.82%

1Y

22.80%

5Y*

12.93%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of PTPI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-28.92%-66.49%
2024-14.18%42.15%-13.95%-54.32%-9.17%-25.41%-11.35%-17.98%7.21%3.64%-25.84%43.55%-72.06%
202311.59%-19.23%-33.57%208.24%-45.81%-12.88%97.54%-36.41%-32.16%-17.34%11.89%-11.88%-39.48%
2022-48.05%-20.23%13.04%-27.56%-13.72%-13.85%-5.48%-17.38%-22.26%-5.88%-14.38%-43.31%-93.00%
2021-23.64%-0.89%12.01%-13.67%-5.90%3.30%-2.88%-25.99%-11.11%-13.00%64.37%16.43%-24.32%
202010.28%10.28%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PTPI is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PTPI is 88
Overall Rank
The Sharpe Ratio Rank of PTPI is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of PTPI is 55
Sortino Ratio Rank
The Omega Ratio Rank of PTPI is 66
Omega Ratio Rank
The Calmar Ratio Rank of PTPI is 22
Calmar Ratio Rank
The Martin Ratio Rank of PTPI is 1212
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Petros Pharmaceuticals Inc (PTPI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for PTPI, currently valued at -0.62, compared to the broader market-2.000.002.00-0.621.74
The chart of Sortino ratio for PTPI, currently valued at -1.47, compared to the broader market-4.00-2.000.002.004.006.00-1.472.36
The chart of Omega ratio for PTPI, currently valued at 0.81, compared to the broader market0.501.001.502.000.811.32
The chart of Calmar ratio for PTPI, currently valued at -0.91, compared to the broader market0.002.004.006.00-0.912.62
The chart of Martin ratio for PTPI, currently valued at -1.27, compared to the broader market-10.000.0010.0020.0030.00-1.2710.69
PTPI
^GSPC

The current Petros Pharmaceuticals Inc Sharpe ratio is -0.62. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Petros Pharmaceuticals Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.62
1.74
PTPI (Petros Pharmaceuticals Inc)
Benchmark (^GSPC)

Dividends

Dividend History


Petros Pharmaceuticals Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-99.72%
-0.43%
PTPI (Petros Pharmaceuticals Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Petros Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Petros Pharmaceuticals Inc was 99.72%, occurring on Feb 20, 2025. The portfolio has not yet recovered.

The current Petros Pharmaceuticals Inc drawdown is 99.72%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.72%Dec 29, 20201041Feb 20, 2025
-18.8%Dec 3, 20203Dec 7, 202013Dec 24, 202016

Volatility

Volatility Chart

The current Petros Pharmaceuticals Inc volatility is 84.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
84.62%
3.01%
PTPI (Petros Pharmaceuticals Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Petros Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Petros Pharmaceuticals Inc.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab